Gain‐of‐function mutations in Nav1.7 are associated with familial erythromelalgia [20], small‐fiber neuropathy [21], and diabetic neuropathic pain [22], while inhibition of Nav1.7 function helps alleviate neuropathic and inflammatory pain [23, 24, 25]. This evidence concerns the gene SCN9A and primary erythermalgia.